头颈部横纹肌肉瘤质子束治疗后的失败模式
46例头颈部横纹肌肉瘤患儿于2006至2015年入组前瞻性登记方案,均接受化疗联合质子束治疗。中位随访3.9年,5年总生存率76%、无进展生存率57%、局部控制率84%;肿瘤大于5 cm和诊断时颅内延伸预测局部失败风险升高,颅内延伸患者化疗第4周后延迟放疗预测复发风险升高。
要点
- 质子束治疗头颈部横纹肌肉瘤5年局部控制率84%,5年总生存率76%。
- 肿瘤大于5 cm(HR 6.49,p=0.03)和诊断时颅内延伸(HR 5.21,p=0.03)预测局部失败风险升高。
- 颅内延伸患者化疗第4周后延迟放疗预测复发风险升高(HR 10.49,p=0.006)。
核心结论
- 质子束治疗头颈部横纹肌肉瘤可获得良好的局部控制,与既往光子放疗数据相比晚期毒性谱更有利。
- 观察结果支持正在进行的针对较大肿瘤患者放疗剂量递增的试验努力。
- 但这些数据引起了对颅内延伸患者失败过多的担忧。
研究设计与样本
- 2006年至2015年间46例头颈部横纹肌肉瘤患者入组前瞻性登记方案。
- 所有患者均接受化疗与质子束治疗联合治疗。
- 25例(54%)为脑膜旁肿瘤,其中11例(24%)有颅内延伸;13例(28%)原发肿瘤大于5 cm。
- 中位环磷酰胺等效总剂量为13.2 g/m2(范围0-16.8 g/m2)。
- 中位放疗剂量为50.4 Gy(RBE)(范围36 Gy[RBE]-50.8 Gy[RBE])。
主要发现
- 中位随访3.9年,5年总生存率为76%,5年无进展生存率为57%。
- 17例(37%)发生复发,包括7例局部失败;5年局部控制率为84%。
- 肿瘤大于5 cm预测局部失败风险升高(HR 6.49,p=0.03),诊断时存在颅内延伸亦如此(HR 5.21,p=0.03)。
- 6例复发发生于颅内延伸患者,均包含中枢神经系统复发成分,伴柔脑膜病变和/或含颅内成分的局部失败。
- 颅内延伸患者化疗第4周后延迟放疗预测复发风险升高(HR 10.49,p=0.006)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pediatric patients with rhabdomyosarcoma (RMS) of the head and neck (H&N) are treated with multimodal therapy, often with radiotherapy (RT) as definitive local therapy. We report on the patterns of failure following proton beam therapy (PBT) for H&N RMS. METHODS: Forty-six H&N RMS patients were enrolled on a prospective registry protocol between 2006 and 2015. All were treated with a combination of chemotherapy (ChT) and PBT. Most patients (25 patients, 54%) had parameningeal tumors, of which 11 (24%) had intracranial extension (ICE). Thirteen patients (28%) had primary tumors greater than 5 cm. Median total cyclophosphamide (CPM) equivalent dose was 13.2 g/m2 (range 0-16.8 g/m2). Median RT dose was 50.4 Gy(RBE) (range 36 Gy[RBE]-50.8 Gy[RBE]). RESULTS: With median follow-up of 3.9 years, five-year overall survival was 76%, and five-year progression-free survival was 57%. Seventeen patients (37%) experienced relapse, including 7 with local failure (LF). Five-year local control (LC) was 84%. Tumor size greater than 5 cm predicted increased risk of LF (hazard ratio [HR] 6.49, p = 0.03), as did the presence of ICE at diagnosis (HR 5.21, p = 0.03). Six relapses occurred in patients with ICE; all included a component of central nervous system relapse, with leptomeningeal disease and/or LF with an intracranial component. Delayed RT delivery after week 4 of ChT predicted increased risk of relapse for ICE patients (HR 10.49, p = 0.006). CONCLUSIONS: PBT confers excellent LC, and a favorable late toxicity profile as compared with prior photon RT data. Our observations support ongoing trial efforts to dose-escalate RT for patients with larger tumors. However, these data raise concerns regarding excess failures among patients with ICE.
引用
- Ludmir EB, Grosshans DR, McAleer MF, et al. Patterns of failure following proton beam therapy for head and neck rhabdomyosarcoma. Radiother Oncol. 2019. PMID: 31005208. doi:10.1016/j.radonc.2019.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。